A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.
← catalyst calendarSponsored by Vyne Therapeutics Inc. (industry) · VYNE — their whole pipeline →.
Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
205actual
Sites
49
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Business Decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-04 | actual | When the study began enrolling |
| Primary completion | 2025-07-10 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-30 | actual | The whole study's end, after follow-up |
| First posted | 2024-07-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-segmental Vitiligo
Interventions
- Drug: VYN201 Gel
- Drug: Vehicle Gel
Primary outcome
what the primary-completion date above is the date OFTo evaluate the efficacy of VYN201 compared to vehicle at Week 24 in subjects with NSV.
measured Week 24
Permalink · VYNE's whole pipeline · Catalyst calendar · Every registered study · What changed